Roche CEO pay rises as profits fall

Here's a new angle on the Roche-Genentech fracas: Though the Swiss drugmaker saw sales and net income decline--and its stock drop by about one-third--in 2008, CEO Severin Schwan (photo) got a pay boost of almost 50 percent. What's more, Schwan and his team failed to close a deal with partner Genentech, despite six months of negotiating with its board and hunting for financing, BNet Pharma points out.

Nonetheless, Schwan's pay packet grew by, well, a packet. That's 1.6 million Swiss francs, or about $1.4 million. Total 2008 compensation? Some $4.5 million (5.2 million francs), up from $3.1 million (3.6 million francs) in 2007. That's triple what he took home in 2006; back then his compensation was all of $1.4 million or so (1.7 million francs).

Now it's true that $4.5 million in CEO pay pales in comparison with the lavish compensation packages of U.S. execs. But it's the percentage increase--at a time when the company's leading indicators trended downward--that raises our eyebrows. We wonder what Roche's shareholders think.

- read the post at BNet pharma

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.